ʻO ka hypertriglyceridemia ʻohana

ʻO ka hypertriglyceridemia ʻohana kahi maʻi maʻamau i iho ʻia i waena o nā ʻohana. Hoʻokumu ia i kahi pae kiʻekiʻe ma mua o ka maʻamau o nā triglycerides (kahi ʻano momona) i ke koko o ke kanaka.

ʻO ka hypertriglyceridemia ʻohana ka mea nui i hoʻokumu ʻia e nā kīnā genetika i hui pū ʻia me nā kumu kaiapuni. ʻO ka hopena, hoʻopili ʻia ke ʻano i loko o nā ʻohana. Pehea ka ʻino o ka maʻi e hiki ke loli ma muli o ka moekolohe, ka makahiki, ka hoʻohana ʻana i ka hormone, a me nā kumuʻai.

Loaʻa i nā poʻe me kēia ʻano nā kiʻekiʻe kiʻekiʻe o lipoprotein haʻahaʻa haʻahaʻa (VLDL). ʻO ka LDL kolamu a me ka HDL kolokoli haʻahaʻa pinepine.

I ka hapanui o nā hihia, ʻike ʻole ʻia ka hypertriglyceridemia ʻohana a hiki i ka wā ʻōpio a i ʻole ke oʻo makua. ʻO ka nui, hyperglycemia (pae kiʻekiʻe o ke kō glucose) a me nā kiʻekiʻe kiʻekiʻe o ka insulin i laila pū kekahi. Hiki i kēia mau mea ke kumu i nā pae triglyceride kiʻekiʻe aʻe. ʻO ka wai ʻona, kahi papaʻai kiʻekiʻe i nā haʻuki, a me ka hoʻohana ʻana o estrogen hiki ke hōʻeha i ke ʻano.

Loaʻa paha kēia ʻano iā ʻoe inā he moʻolelo ʻohana kāu o ka hypertriglyceridemia a i ʻole ka maʻi puʻuwai ma mua o ka makahiki 50.

ʻAʻole paha ʻoe e ʻike i kekahi ʻōuli. Hiki i kekahi poʻe me kēia ʻano ke loaʻa i ka maʻi o ke aʻa coronary i ka wā ʻōpio.

E hana ka mea mālama ola i kahi hoʻokolohua kino a nīnau e pili ana i ka mōʻaukala a me nā ʻōuli o kou ʻohana.

Inā loaʻa iā ʻoe kahi moʻolelo ʻohana o kēia ʻano, pono ʻoe e hōʻoia i ke koko e nānā i ka lipoprotein haʻahaʻa haʻahaʻa (VLDL) a me nā pae triglyceride. Hōʻike pinepine nā hoʻokolohua koko i kahi hoʻonui akahai a hoʻonui i nā triglycerides (ma kahi o 200 a 500 mg / dL).

E hana pū ʻia paha kahi ʻike pilikia o ka coronary.

ʻO ka pahuhopu o ka mālama ʻana e kaohi i nā kūlana i hiki ke hāpai i nā pae triglyceride. Hoʻopili kēia i ka momona, hypothyroidism, a me ka maʻi kō.

E haʻi paha kāu mea hāʻawi iā ʻoe ʻaʻole e inu i ka ʻalekohola. Hiki i kekahi mau lāʻau hoʻomalu hānau ke hāpai i nā pae triglyceride. E kamaʻilio i kāu mea hāʻawi e pili ana i kāu makaʻikaʻi ke koho ʻana e lawe i kēia mau lāʻau.

Hoʻopili pū ka mālama ʻana i ka hōʻalo ʻana i nā calorie nui a me nā meaʻai kiʻekiʻe i loko o nā momona momona a me nā huaʻā.

Pono ʻoe e ʻai i ka lāʻau inā kiʻekiʻe ke kiʻekiʻe o kāu pae triglyceride ma hope o ka hoʻololi ʻana i ka papaʻai. Ua hōʻike ʻia ʻo Nicotinic acid, gemfibrozil, a me fenofibrate e hoʻohaʻahaʻa i nā pae triglyceride i ka poʻe me kēia ʻano.

ʻO ka lilo ʻana o ke kaupaona a me ka mālama ʻana i ka maʻi maʻisā ma lalo o ke kaohi kōkua e hoʻomaikaʻi i ka hopena.

Komo pū nā pilikia:

• ʻO Pancreatitis
• Maʻi maʻi ʻaʻai Coronary

ʻO ka ʻimi ʻana i nā lālā o ka ʻohana no triglycerides kiʻekiʻe e ʻike koke i ka maʻi.

ʻAno IV hyperlipoproteinemia

• Papaʻai olakino

ʻO Genest J, Libby P. Nā maʻi lipoprotein a me nā maʻi maʻi ʻōpū. I: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. ʻO ka maʻi puʻuwai ʻo Braunwald: He puke aʻo no ka lāʻau Cardiovascular. 11th hua. Piladelapia, PA: Elsevier; 2019: chap 48.

Robinson JG. Nā maʻi o ka lipid metabolism. I: Goldman L, Schafer AI, eds. ʻO ka lāʻau lapaʻau Goldman-Cecil. 26th ed. Piladelapia, PA: Elsevier; 2020: chap 195.